News

BioStat® Research
& Development Centre

2024 2023 2022 older
Biostat 6th consecutive year as research and development center
18
October
2024
Biostat 6th consecutive year as research and development center
The Minister of Development and Technology has decided to maintain Biostat's status as a research and development...
Study on generalized myasthenia gravis for AstraZeneca
09
October
2024
Study on generalized myasthenia gravis for AstraZeneca
The Biostat Research and Development Center will carry out another project in collaboration with AstraZeneca. T...
Study of new solutions in surgery for Corza Medical
26
August
2024
Study of new solutions in surgery for Corza Medical
The Biostat Research and Development Center has signed an agreement with Corza Medical to conduct a PASS study in the...
Aneta Piechaczek, Phd from Biostat co-authors a wcientific article
21
August
2024
Aneta Piechaczek, Phd from Biostat co-authors a wcientific article
Marek Kluszczyński, MD, who specializes in the rehabilitation of children and adolescents, has published a scientific...
Biostat will conduct a medical experiment for Stallergenes Greer
17
July
2024
Biostat will conduct a medical experiment for Stallergenes Greer
Biostat Research and Development Center has signed an agreement with a pharmaceutical company Stallergenes Greer to c...
Cooperation of Biostat and Medinice. Doctors used the CoolCryo system during surgery
09
July
2024
Cooperation of Biostat and Medinice. Doctors used the CoolCryo system during surgery
The innovative CoolCryo® system for cardiac cryoablation, for which Biostat is conducting a clinical trial,...
Biostat will conduct a non-interventional study for Adamed Pharma
27
June
2024
Biostat will conduct a non-interventional study for Adamed Pharma
A non-interventional study among cardiology patients - this is a new field of cooperation between the Biostat R...
Biostat listed in the Forbes ranking
21
May
2024
Biostat listed in the Forbes ranking
For another year in a row, Biostat Research and Development Center has been recognized in the ranking of the most dyn...
Biostat and MSD Polska collaborate on lung cancer study
16
May
2024
Biostat and MSD Polska collaborate on lung cancer study
The Biostat Research and Development Centre starts cooperation with the MSD Polska pharmaceutical company. ...
Post-stroke aphasia. Biostat in a clinical trial in the US
15
February
2024
Post-stroke aphasia. Biostat in a clinical trial in the US
Biostat's Research and Development Center has prepared a randomization system for a clinical trial being conducte...
It's been a good year! Summary of 2023 at Biostat
12
February
2024
It's been a good year! Summary of 2023 at Biostat
It's been a good year! Summary of 2023 at Biostat We summarize 2023 at Biostat Group. We are p...
21
May
2024
Biostat listed in the Forbes ranking
21
May
2024

Biostat listed in the Forbes ranking

For another year in a row, Biostat Research and Development Center has been recognized in the ranking of the most dynamically developing companies, prepared by Forbes magazine.

 

Forbes editors create the "Forbes Diamonds" ranking in cooperation with the analytical company Dun & Bradstreet Poland.

 

Once again, among the distinguished companies in the revenue range between PLN 5 and 50 million was Biostat Research and Development Center.
 


Distinction in the "Forbes Diamonds" ranking confirms us in the conviction that our business strategy is right. And it is based on a consistent focus on innovation, in which the skillful use of AI and machine learning technologies is becoming increasingly important,"

comments Rafal Piszczek - Biostat's CEO.




The Forbes Diamonds ranking included companies that have increased their value most rapidly in the last three years. Included were companies that submitted financial statements to the National Court Register or directly to Dun & Bradstreet Poland. Companies in bankruptcy or liquidation were eliminated. Forbes Diamonds were awarded to those companies that had a positive financial result and a cooperation risk index above 4 according to the rating.

 

The awarded companies were divided into three categories depending on sales revenue in the last fiscal year: small companies with a revenue of PLN 5 to 50 million, medium-sized companies with a revenue of PLN 50 to 250 million, and large companies with a revenue of more than PLN 250 million.

 

> Forbes Diamonds for Biostat in 2023

> Biostat: full-service CRO in Poland and CEE

 

Copyright© 2023 Biostat